Background. Chronic kidney disease is common after heart transplantation, and is related to ciclosporin (CsA) therapy. We compared the safety and efficacy of two ciclosporin withdrawal regimens. Methods. CsA was stopped and sirolimus (SRL) commenced immediately and the transfer was covered with prednisolone. Those on azathioprine (AZA) were transferred to MMF. In protocol A, the SRL target concentration was 16 (12-20) ng/ml; in protocol B, the target concentration was 7(5-10) ng/ml, but mycophenolate (MMF) and steroids were commenced prior to the transfer. Results. Baseline characteristics were similar in both groups except that group B were switched later after transplantation. Renal function improved significantly in both groups; this was maintained up to 1 year. Two patients in group A experienced acute rejection (ISHLT grade 3A or 2R); none was seen in group B. Six patients (46%) remained on protocol A and 22 (85%) remained on protocol B at 1 year. Conclusions. MMF-SRL substitution resulted in a rapid but partial improvement in renal function; the lower dose SRL regimen was better tolerated.
Introduction
Calcineurin inhibitors (CNIs) are the mainstay of immunosuppression after heart transplantation [1, 2] , but are associated with nephrotoxicity [3, 4] , with 42% of patients showing substantial renal impairment at 10 years [2] .
Studies of CNI withdrawal after kidney transplantation have shown improved renal function [5] [6] [7] [8] [9] [10] [11] . Several studies have shown improved renal function after heart transplantation. However, alternatives such as mycophenolate mofetil (MMF) and sirolimus (SRL) may not provide as effective prophylaxis against allograft rejection [12] .
Here we have retrospectively compared the outcomes of two CNI-elimination protocols for heart transplant recipients who were experiencing nephrotoxicity.
Methods
Patients with deteriorating renal function that was judged to be due to chronic ciclosporin (CsA) nephrotoxicity were selected; a nephrologist reviewed all patients. Exclusions were heterotopic heart transplants, patients with acute or chronic infection, known intolerance to MMF and those patients who were clinically unstable or had recent acute rejection; the patient characteristics are shown in Table 1 .
Protocol A was used from July 2002 to August 2003 and protocol B from March 2004 to February 2007. In both protocols, CsA was stopped immediately, and SRL was commenced ( Figure 1 ). In protocol A, the transfer period was covered with prednisolone; initially, we used 1 mg/kg/day (max. 70 mg) in three patients, this was subsequently reduced to 30 mg daily to reduce side effects; the prednisolone was tapered and discontinued where possible. The target SRL blood concentration was 16 (12-20 ng/ml).
In protocol B, those taking azathioprine (AZA) were transferred to MMF 0.5-1 g twice daily 2 weeks prior to the intended switch. Prednisolone 10 mg daily was also started; those already on steroids at ≥10 mg prednisolone had this continued and then gradually tapered. The SRL target concentration was 7 (5-10) ng/ml.
Haematology, biochemistry and SRL concentrations were monitored. The estimated glomerular filtration rate (eGFR) was calculated using the four-variable modified diet in renal disease (MDRD) formula [13] . Cardiac function was assessed clinically by echocardiography and, if indicated, by endomyocardial biopsy [14] .
All treatment was given on the basis of clinical need, and the local ethics committee gave permission to analyse the data retrospectively.
Results
Renal function improved in both groups after changing to SRL (Figures 2 and 3 ). This was evident at 1 month and was maintained at 1 year; there was no difference between the two groups. However, there was also a significant increase in proteinuria (Table 2) ; patients were mildly
Transfer from CsA to MMF-SRL immunosuppression for chronic renal disease after heart transplantation 3873 there was an initial increase in eGFR at 1 month (group A P = 0.02, group B P = 0.02) that then remained stable for 1 year; this was similar in both treatment groups (intention-to-treat analysis shown). anaemic (Table 1) , but there was no change in haemoglobin after starting SRL ( Table 2 ). The increase in eGFR was greater in those who were converted earlier after heart transplantation (r 2 = 0.1886, P = 0.01) (Figure 4) .
The reasons for withdrawal are shown in Tables 3 and 4 . 
Discussion
This study demonstrates that renal dysfunction after cardiac transplantation is rapidly, although only partially, reversible following CsA withdrawal. It seems likely that the residual dysfunction relates to structural damage in the kidneys and this is consistent with other studies [8] [9] [10] [11] 15] . In addition, CsA is not the only factor related to CKD after transplantation [16] . This is the first study to compare the safety and tolerability of two different SRL-MMF regimens. The high-dose SRL regimen (protocol A) used the recommendations current at that time for renal transplantation [5] , but it was associated with frequent side effects and a high early withdrawal rate. Furthermore, despite high SRL concentrations, breakthrough ACR was seen. The second regimen had lower concentrations of SRL but overlapped the immunosuppressants during the transfer. This was better tolerated and ACR did not occur; furthermore, there were fewer early withdrawals from this regimen. The overall in- cidence of acute cellular rejection was 2 out of 39 patients (5.1%) at 1 year and this is similar to the 6% reported by Hunt et al. [9] . The improvement in renal function showed an inverse correlation with time after transplantation when CsA was stopped, indicating that reversibility decreases with prolonged CsA exposure.
There were no deaths within 1 year, but six later (Table 6) , two due to malignancy, however, they occurred 9 and 15 years post-transplantation. A link between SRL and malignancy is uncertain because this is a known late complication of transplantation [2] . Other side effects that were observed have been reported previously [17] [18] [19] [20] [21] [22] [23] [24] [25] (Table 3) .
Proteinuria has been reported with SRL treatment in renal [26] and, more recently, cardiac transplantation [27] . In our study, most patients already showed some degree of proteinuria, but this increased in both groups after the conversion ( Table 2) .
Limitations of this study are that it was a retrospective non-randomized comparison, more patients were treated with protocol B and these patients were switched later after their transplant. 
Conclusion
CKD after cardiac transplantation was rapidly but only partially reversible following withdrawal of CsA. The staged transfer used in protocol B was well tolerated and did not result in acute rejection. Improvement in eGFR occurred early suggesting that it had a functional basis; renal function then stabilized over the ensuing 12 months. However, proteinuria increased. Therefore, an even longer follow-up will be required to assess the ultimate effect of CsA withdrawal on renal function. From the renal perspective, earlier transfer to a non-CNI regimen would be desirable but this has to be balanced against the risk of rejection that is higher early after transplantation.
